Hackensack, NJ - According to Tom Bergeron of NJBiz, "Hackensack University Medical Center was once again named the top hospital in New Jersey by the prestigious U.S. News & World Report Best Hospitals rankings, which were released Tuesday morning. Hackensack was nationally ranked in five of the identified specialties and rated “high performing” in six others, helping it earn the No. 4 overall honor in the New York City area."
New Brunswick, NJ - A new study recently published in the journal ACS Nano revealed a new technique to trigger muscle cell differentiation from adult stem cells using a genetic approach. The study is entitled “Inducing Stem Cell Myogenesis Using NanoScript” and was conducted by researchers at Rutgers, The State University of New Jersey in the United States and the Kyoto University in Japan.
Stratford, NJ - According to Emily Bader of NJBiz, "Rowan University School of Osteopathic Medicine announced Friday that it has received a $2.55 million grant from the Health Resources Services Administration to improve geriatric health by establishing the New Jersey Geriatrics Workforce Enhancement Program. The grant will be used to train and equip health care providers statewide, according to Dr. Thomas Cavalieri, dean of the Rowan University School of Osteopathic Medicine."
Kenilworth, NJ - According to Eric Strauss of NJBiz, "Merck is acquiring an Israeli biopharmaceutical company for $95 million in cash, the drugmaker announced Tuesday. The Kenilworth-based company’s deal for cCAM Biotherapeutics, which is focused on cancer immunotherapies, could potentially include up to $510 million in milestone payments, it said."
New Brunswick, N.J. – Several physicians at Rutgers Cancer Institute of New Jersey have been named as a ‘Top Cancer Doctor’ by Newsweek magazine. Newsweek just released the list of the nation’s top physicians for cancer care in conjunction with Castle Connolly Medical Ltd., which publishes America’s Top Doctors. Based on peer nominations, attributes such as board certification, clinical skills, training, years in practice, administrative posts, achievements and other criteria are reviewed and assessed by a physician-led research team assembled by Castle Connolly. According to Castle Connolly, nearly 100,000 nominations are received each year for the honor. In New Jersey alone, 40 Top Cancer Doctors were named to the national list – nine are from the Cancer Institute of New Jersey.
Washington D.C. - Opposition to H.R. 9, the Innovation Act, has successfully removed the patent reform legislation from the House's pre-recess schedule. The collective voice of the life sciences community, including BioNJ and BIO, was raised in overwhelming opposition to the current version of the bill, which does not provide adequate reform to the IPR system of patent challenges at the U.S. Patent & Trademark Office (PTO).
Tinton Falls, NJ - At the Internet of Medical Things speakers from Johnson & Johnson, the FDA, Sage Bionetworks, and WAM Consulting Group presented their perspectives on issues key to developing safeguards for drug development data, patient records, and medical devices. Dr. Suzanne Schwartz, the FDA’s Director for Emergency Preparedness, addressed the agency’s approach to building internal communications and public private partnerships to enhance cybersecurity throughout the healthcare system. While it’s not always easy to find a “front door” for collaborating with the FDA, she mentioned National Healthcare & Public Health Critical Infrastructure Protection (http://www.nhisac.org/).
NJ Resources Support Serial Entrepreneur David Fischell’s Mission to Create Life-Saving Medical Devices
Trenton, NJ - The New Jersey Economic Development Authority (EDA) continues its series highlighting how entrepreneurs and investors are helping to build New Jersey’s technology ecosystem. Serial entrepreneur Dr. David Fischell, of Fair Haven, has founded and led more than a dozen medical device companies to success in the last 20 years. To Fischell, developing medical devices is a family affair. David, along with his father Dr. Robert Fischell, a physicist, and his brother Dr. Tim Fischell, a cardiologist, started New Providence-based Svelte Medical Systems in 2007.
New Brunswick, NJ - If you find yourself downing that extra piece of chocolate fudge cake even though you're not hungry, it might be the absence of a hormone in your brain that's causing you to overeat purely for pleasure. In a new Rutgers Robert Wood Johnson Medical School study published in Cell Reports, researchers found that when the hormone glucagon like peptide-1 (GLP-1) was reduced in the central nervous system of laboratory mice, they overate and consumed more high fat food.
Kenilworth, NJ - Merck, known as MSD outside the United States and Canada, announced today that the company's commitment to HIV and AIDS, which started with a research and development program initiated in the mid-1980s during the early years of the epidemic, is now entering its fourth decade. To commemorate Merck's 30 years of commitment in this area, the company is launching a new effort, “Positively Committed.” The campaign highlights the company’s contributions, including the development of innovative therapies to address the unmet medical needs of people infected with HIV-1.
Princeton, NJ - Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational compound BMS-663068 when used in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in heavily treatment-experienced adult patients. BMS-663068 is an oral prodrug of the molecule BMS-626529 and first-in-class HIV-1 attachment inhibitor. The attachment inhibitor is designed to work differently than entry inhibitors, a current class of drugs that targets co-receptors’ activity or fusion after HIV attaches to the CD4+ host cell. BMS-663068 is thought to work at an earlier point in the replication process to prevent the virus’ initial interaction with immune cells entirely, and thus blocks its entry into the cell.
Need another reason to understand why the Rutgers-UMDNJ merger was so big? Listen to the dean of the medical school
Newark, NJ - According to Tom Bergeron of NJBiz, "Dr. Robert Johnson had been associated with UMNDJ for much of his life. And he's the first to admit that when he heard the school was merging with Rutgers University, he didn't think it would make much of a difference — other than changing a few signs, he joked.
Trenton, NJ - The New Jersey Economic Development Authority (EDA) continues its series highlighting how entrepreneurs and investors are helping to build New Jersey’s technology ecosystem: In 1999, scientist-turned-entrepreneur Navneet Puri earned his PhD in Pharmaceutical Sciences from Rutgers University and went on to found InnoPharma, Inc. in Piscataway just a few years later. The research and development pharmaceutical company, focused on developing complex generic and innovative specialty products in injectable and ophthalmic dosage forms, was ultimately acquired by pharmaceutical giant Pfizer last year. Under Puri’s leadership, InnoPharma had more than 30 products in various stages of development, including 10 generic products that had received Food and Drug Administration approval.
Galloway Township, NJ – Stockton University today welcomed the inaugural group of students in the Atlantic City cohort of Philadelphia University’s Master of Science in Physician Assistant Studies program. Stockton and Philadelphia University (PhilaU) are partnering with Reliance Medical Group to offer this Atlantic City-based program in a growing field of the health sciences.
Summit, NJ – According to New Jersey Business Magazine, “Celgene Corporation and San Diego-based Receptos, Inc. sign a definitive agreement in which Celgene has agreed to acquire Receptos. Under the terms of the merger agreement, Celgene will pay $232.00 per share in cash, or a total of approximately $7.2 billion, net of cash acquired.”
Do not miss a single innovative moment and sign up for our newsletter!